AM-710 / Exavir Therapeutics - LARVOL DELTA

Preclinical Characterization of AM-710, a Novel Ultra-Long-Acting Small-Molecule GLP-1R Agonist (OBESITY WEEK 2025) - "These data support the ultra-long-acting profile of AM-710, a novel prodrug of the small molecule GLP1R agonist orforglipron with the potential to provide infrequent dosing with improved peak-to-trough PK. Based on its favorable in vivo PK/PD profile, further investigation of AM-710 is warranted, including progression to IND-enabling studies."

Preclinical • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Aion Medicines Presents Data at ObesityWeek Demonstrating Ultra-long-acting Pharmacokinetics and Pharmacodynamic Effects of AM-710, a Potential Best-in-class GLP-1 Receptor Agonist and the Longest Acting Incretin Identified to Date (Businesswire) - "AM-710 is an ultra-long-acting prodrug of orforglipron, with >150-fold half-life extension, enabling once every 3 month and once every 6 month dosing or longer. A single subcutaneous dose of AM-710 produced and maintained >15% weight loss in hGLP1R diet-induced-obese (DIO) mice over a one-month study period. AM-710 treatment produced greater, sustained improvements in fasting blood glucose, oral glucose tolerance testing, weight loss and fat mass loss versus daily oral orforglipron."

Preclinical • Obesity